ReportOpen · FreeRwanda

Rwanda pharmaceutical market outlook

What is driving demand for medicines in Rwanda, how much of it is met by imports, and which manufacturing capacity is planned or under construction. A dated baseline for anyone planning to produce, distribute or invest.

Published 1 Nov 2026 · Data as of Jun 2026 · Source: National trade statistics, 2021–2025 Sample data

Author Eric Nshimiyimana, MSc Health Economics·Reviewed by Dr. Claudine Mukamana, PharmD, MPH·Next update planned Q2 2027

Summary of findings

Three findings stand out. Imports still supply most medicines by value, though the share has edged down for three years. Local production is concentrated in a small number of oral solid and liquid lines. And planned capacity, if built on schedule, would roughly double local output of essential tablets by 2029. Every figure on this page is sample data for design review, not a real statistic.

Wide view of a distribution warehouse
Sample figure · not real data71%Share of medicines, by value, that were imported in 2025Source: National trade statistics (sample) · Period: Jan–Dec 2025 · Retrieved 14 Oct 2026 · Estimate

Methodology and limitations

The report draws on official import statistics, regulator registers and company disclosures. Where figures are estimated, the method and assumptions are given beside the estimate. Limitations include reporting lags in trade data and incomplete disclosure of planned capacity.

Citations

  1. National trade statistics. Imports of pharmaceutical products by HS chapter 30, 2021–2025. Retrieved 14 Oct 2026. · Sample citation
  2. Medicines regulator. Register of licensed pharmaceutical manufacturers, status at 30 Jun 2026. Retrieved 2 Oct 2026. · Sample citation
  3. Investment promotion agency. Registered manufacturing projects in the health sector, 2023–2026. Retrieved 6 Oct 2026. · Sample citation